{"_id": "64fe7f991544b4d920499d0c", "nctID": "NCT02298959", "Not yet fixed MQL": "{\n\"and\": [\n{\n\"$or\": [\n{\n\"$or\": [\n{\"cancer type\": \"metastatic disease from any solid tumor\"},\n{\"cancer type\": \"metastatic melanoma\"},\n{\"cancer type\": \"renal cell carcinoma\"},\n{\"cancer type\": \"ovarian cancer\"},\n{\"cancer type\": \"colorectal cancer\"},\n{\"cancer type\": \"PD-1 resistant melanoma\"},\n{\"cancer type\": \"PD-1 resistant renal cancer\"},\n{\"cancer type\": \"sarcoma\"}\n]\n},\n{\n\"$or\": [\n{\"renal cell patients with at least one prior VEGF TKI\"},\n{\"ovarian cancer patients resistant to platinum therapy\"},\n{\"colorectal cancer patients who have failed at least one oxaliplatin-containing regimen\"}\n]\n},\n{\n\"$or\": [\n{\"number of prior therapies for metastatic disease\": {\"$lte\": 2}},\n{\"age\": {\"$gte\": 18}},\n{\"ECOG performance status\": {\"$lte\": 1}},\n{\"estimated life expectancy\": {\"$gt\": 180}},\n{\"leukocytes\": {\"$gte\": 2000}},\n{\"absolute neutrophil count\": {\"$gte\": 1500}},\n{\"platelets\": {\"$gte\": 100000}},\n{\"hemoglobin\": {\"$gte\": 9}},\n{\"serum total bilirubin\": {\"$lte\": 1.5}},\n{\"AST/ALT\": {\"$lte\": 2.5}},\n{\"serum creatinine\": {\"$lte\": 1.5}},\n{\"INR/PT\": {\"$lte\": 1.5}},\n{\"aPTT\": {\"$lte\": 1.5}},\n{\"UPCR\": {\"$lte\": 1}},\n{\"archival tissue available\": true},\n{\"measurable disease based on RECIST 1.1\": true},\n{\"adequate contraception\": true},\n{\"negative pregnancy test\": true},\n{\"willingness to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication for female patients of childbearing potential\": true},\n{\"ability to understand and the willingness to sign a written informed consent document\": true},\n{\"dose expansion part 2 PD-1/PD-L1 resistant or refractory melanoma and renal cell cancer only: subjects must have received prior immunotherapy with an anti-PD-1 or anti-PD-L1 containing regimen and must have progressive or recurrent disease after prior PD-1/PD-L1 directed therapy; primary resistance is determined at the time of initial restaging from initiation of treatment, as evidenced by progression by RECIST 1.1; acquired resistance would be a subject who had a best overall RECIST response of stable disease, partial response, or complete response confirmed radiographically by a second scan who subsequently developed progressive disease by RECIST 1.1 at any time thereafter\": true},\n{\"dose expansion part 2 sarcoma only: subjects must have received standard of care treatment\": true}\n]\n}\n]\n},\n{\n\"$not\": {\n\"$or\": [\n{\"days since chemotherapy, targeted small molecule therapy, or radiotherapy\": {\"$lt\": 28}},\n{\"days since post-operative after major surgery\": {\"$lt\": 28}},\n{\"days since participating in or have participated in a study of an investigational agent or using an investigational device\": {\"$lt\": 28}},\n{\"days since diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy\": {\"$lt\": 7}},\n{\"days since prior monoclonal antibody\": {\"$lt\": 28}},\n{\"known additional malignancy that is progressing or requires active treatment\": true},\n{\"lesions suspected to be at higher-risk for bleeding such as bowel involvement with tumor that invades into the bowel wall or involves the intraluminal component of bowel by imaging or direct visualization or central pulmonary lesions\": true},\n{\"ulcerated skin lesions\": true},\n{\"full anti-coagulant therapy Coumadin\": true},\n{\"poorly-controlled hypertension\": true},\n{\"pregnant or nursing women\": true},\n{\"known brain metastases\": true},\n{\"carcinomatous meningitis\": true},\n{\"previously treated brain metastases who are not stable, have evidence of new or enlarging brain metastases, or are using steroids for at least 7 days prior to trial treatment\": true},\n{\"history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-aflibercept\": true},\n{\"active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents\": true},\n{\"history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator\": true},\n{\"known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\": true},\n{\"received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or ziv-aflibercept\": true},\n{\"uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\": true},\n{\"pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\": true},\n{\"human immunodeficiency virus (HIV) positive and do not meet the eligibility requirements\": true},\n{\"known active hepatitis B or hepatitis C\": true},\n{\"received a live vaccine within 30 days prior to the first dose of trial treatment\": true},\n{\"history within 6 months prior to treatment of myocardial infarction, severe/unstable angina pectoris, coronary artery bypass graft (CABG), New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), stroke or transient ischemic attack (TIA)\": true},\n{\"history within 3 months prior to treatment of grade 3-4 gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic event\": true}\n]\n}\n}\n]\n}"}